• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION RIGIFLEX II; DILATOR, ESOPHAGEAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION RIGIFLEX II; DILATOR, ESOPHAGEAL Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Perforation (2001)
Event Date 05/01/2023
Event Type  Injury  
Manufacturer Narrative
Block d4, h4: the complainant was unable to provide the suspect device upn and lot number.Therefore, the manufacture date and expiration date are unknown.Block g2: literature: tenlik, i (2022), pneumatic dilation in geriatric achalasia patients (2022) 19:508-515.Doi: 10.5152/tjg.2023.22178.Block h6: imdrf patient code e2114 captures the reportable event of perforation.
 
Event Description
Boston scientific corporation became aware of multiple events through the article "pneumatic dilation in geriatric achalasia patients" written by ilyas tenlik, et al.According to the literature, between 1995 and 2020 achalasia patients (over the age of 65 and those under the age of 65 as the control group) received pneumatic dilations with rigiflex ii balloons (30, 35 and 40 mm in diameter) and the effectiveness was evaluated.The study included 143 achalasia patients over 65 years of age and 150 achalasia patients under 65 years of age.Mean age of geriatric patients was 72.7 +/- 5.92 (65-90), and 50.3% of them were male.Follow-up was conducted for a mean of 64.52 +/- 38.73 months.Mean age of nongeriatric patients was 43.07 +/- 11.69 (18-63), and 58.7% of them were male.A gradual dilation method was used in the patients and initial dilation was performed with a 30 mm balloon inflated with approximately 10 psi.After 4-6 weeks of dilation, patients were evaluated, and gradual balloon diameter increase (35 or 40mm balloon) treatments were continued if necessary.Balloon related adverse events were observed in two patients.Perforation developed in two of the 293 patients in total.One patient underwent surgical treatment due to the perforation that developed after the first balloon dilation.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RIGIFLEX II
Type of Device
DILATOR, ESOPHAGEAL
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
300 boston scientific way
marlborough MA 01752
Manufacturer (Section G)
TECHDEVICE CORPORATION
metro free trade zone
building 3 c
heredia
CS  
Manufacturer Contact
carole morley
300 boston scientific way
marlborough, MA 01752
5086834015
MDR Report Key17032221
MDR Text Key316298564
Report Number3005099803-2023-02848
Device Sequence Number1
Product Code PID
Combination Product (y/n)N
Reporter Country CodeTU
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Literature,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 05/31/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received05/31/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received05/09/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Type of Device Usage Unknown
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-